Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) and LivaNova (NASDAQ:LIVN – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.
Risk & Volatility
Fresenius SE & Co. has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500.
Valuation and Earnings
This table compares Fresenius SE & Co. and LivaNova”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Fresenius SE & Co. | $25.87 billion | 1.29 | $1.43 billion | $0.80 | 18.50 |
| LivaNova | $1.39 billion | 3.62 | -$242.47 million | $3.00 | 30.44 |
Fresenius SE & Co. has higher revenue and earnings than LivaNova. Fresenius SE & Co. is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
97.6% of LivaNova shares are owned by institutional investors. 0.3% of LivaNova shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of current recommendations and price targets for Fresenius SE & Co. and LivaNova, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fresenius SE & Co. | 0 | 0 | 3 | 0 | 3.00 |
| LivaNova | 0 | 3 | 9 | 0 | 2.75 |
LivaNova has a consensus price target of $101.22, indicating a potential upside of 10.84%. Given LivaNova’s higher probable upside, analysts plainly believe LivaNova is more favorable than Fresenius SE & Co..
Profitability
This table compares Fresenius SE & Co. and LivaNova’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Fresenius SE & Co. | 6.58% | 10.24% | 4.94% |
| LivaNova | 13.01% | 16.10% | 7.85% |
Summary
LivaNova beats Fresenius SE & Co. on 11 of the 14 factors compared between the two stocks.
About Fresenius SE & Co.
Fresenius SE & Co. KGaA is a German healthcare group headquartered in Bad Homburg. Its businesses include Fresenius Kabi, which supplies medicines, clinical nutrition, infusion therapies and medical technologies, and Fresenius Helios, which operates hospitals in Germany and Spain. Fresenius Kabi serves healthcare providers around the world, while Helios focuses on hospital and healthcare services in Europe. The group traces its origins to a pharmacy in Frankfurt acquired by pharmacist Eduard Fresenius in 1912.
About LivaNova
LivaNova plc is a global medical technology company that develops and manufactures products for cardiovascular care and neuromodulation. The company was formed in 2015 through the combination of Cyberonics and Sorin Group. In neuromodulation, LivaNova’s VNS Therapy system delivers vagus nerve stimulation and is used as an adjunctive treatment for certain people with drug-resistant epilepsy and treatment-resistant depression. Its cardiovascular products support cardiac surgery and include heart-lung machines, oxygenators and related perfusion equipment.
Receive News & Ratings for Fresenius SE & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. and related companies with MarketBeat.com's FREE daily email newsletter.
